Program
toripalimab
Also written as “Toripalimab”, “Toripalimab Injection” and “CM082 plus JS001”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Breast Neoplasms · Melanoma · Stomach Neoplasms · Carcinoma, Transitional Cell, led by 5 companies.
Drug pageToripalimab: every studyMany companies study it; this page follows only the 13 they lead. All 362 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| RemeGenits history only | 54 open or running | phase 2since Mar 17, 2022 | Mar 17, 2022 | none ahead |
| Mabwell (Shanghai) Bioscience | 33 open or running | phase 3since Sep 9, 2024 | Sep 25, 2023 | Dec 31, 2026phase 2 · NCT06079112 |
| Coherus Oncologyits history only | 22 open or running | phase 4since Jun 10, 2024 | Jun 10, 2024 | Dec 2027phase 4 · NCT06457503 |
| Suzhou Zelgen Biopharmaceuticalsits history only | 21 open or running | phase 2since Aug 3, 2020 | Aug 3, 2020 | none ahead |
| CSPC Pharmaceutical Groupits history only | 10 open or running | phase 3since Dec 12, 2018 | Dec 12, 2018 | none ahead |
Also a collaborator on its studies: Medpace.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Mabwell (Shanghai) Bioscience only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jun 9, 2018Named toripalimabINNProposed as its International Nonproprietary Name in WHO's List 119 · before, JS001
- Sep 25, 2023First study: phase 2 study in Advanced Urothelial CarcinomaFirst studyNCT06079112 · 100 planned · China
- Sep 9, 2024Phase 3 study in Carcinoma, Transitional CellNCT06592326 · 460 planned · China
- Jan 13, 2025Phase 2 study in Carcinoma, Transitional CellNCT06823427 · 60 planned · China
Ahead
- Dec 31, 2026Primary completion: phase 2 study in Advanced Urothelial CarcinomaNCT06079112
- Sep 2027Primary completion: phase 3 study in Carcinoma, Transitional CellNCT06592326
TargetBeta
“Programmed cell death protein 1 antagonist”ChEMBL 37, by rule
Other programs on PDCD1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivonescimabrule | Akeso | phase 3 | 48 |
| rilvegostomig | AstraZeneca | phase 3 | 24 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| tivunatamig | Pfizer | phase 3 | 15 |
| nilvanstomigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 15 |
| pucotenlimabrule | taizhou-hanzhong-biomedical-co-ltd | phase 3 | 15 |
| enlonstobartrule | CSPC Pharmaceutical Group | phase 3 | 15 |
| ezabenlimab | Boehringer Ingelheim | phase 3 | 13 |
| Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363rule | Innovent Biologics | phase 3 | 10 |
| rulonilimabrule | Lunan Pharmaceutical Group | phase 3 | 9 |
| Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 | Sino Biopharmaceutical | phase 3 | 4 |
Studies
All 3 Mabwell (Shanghai) Bioscience leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06823427Carcinoma, Transitional Cell · China | 2 | Recruiting | Jun 2026 | 60 |
| NCT06592326Carcinoma, Transitional Cell · China | 3 | Recruiting | Sep 2027 | 460 |
| NCT06079112Advanced Urothelial Carcinoma · China | 2 | Recruiting | Dec 31, 2026 | 100 |
How it is read
Names in the registry
- “Toripalimab”, 14 entries
- “Toripalimab Injection”, 3 entries
- “CM082 plus JS001”, 3 entries
- “ABO2109 Injection;Toripalimab”, 2 entries
- “JS001”, 2 entries
Codes read as this program: JS001.
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 4 studies
- Breast Neoplasms, 3 studies
- Melanoma, 3 studies
- Stomach Neoplasms, 2 studies
- Carcinoma, Transitional Cell, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.